DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer
Retrieved on:
Wednesday, January 5, 2022
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, KLK1, Medicine, Therapy, COVID-19, University, Chronic kidney disease, Kidney, Form 10-K, Vascular dementia, School, Oxidative stress, Company, Stroke, Patient, State University of New York Upstate Medical University, Pi1 Gruis, Fibrosis, Lists of diseases, U.S. Securities and Exchange Commission, Public health, Pfizer, Neurogenesis, CEO, Hypertension, Clinical trial, AIS, FDA, Inflammation, Private Securities Litigation Reform Act, DMAC, Grinnell College, Retinopathy, Terminology, Employment, Associate, Risk, Doctor of Medicine, Drug development, Nasdaq, Standard of care, Nitric oxide, Annual report, Urine, Iowa State University, Roche, Nature, Pharmaceutical industry, Science, Microbiology, DM199, DiaMedica Therapeutics Inc., DM199, DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Kirsten Gruis, M.D.
Key Points:
- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Kirsten Gruis, M.D.
- We are delighted to welcome Dr. Gruis to the DiaMedica team as Chief Medical Officer, said Rick Pauls, CEO of DiaMedica.
- Prior to joining DiaMedica, Dr. Gruis served as Chief Medical Officer for Edgewise Therapeutics, Neuromuscular Franchise Head at Roche, Chief Medical Officer of Agilis Biotherapeutics, Inc. and a number of additional senior clinical development roles at companies including Wave Life Sciences Ltd., Idera Pharmaceutics, Inc., Alynylam Pharmaceuticals Inc. and Pfizer Inc.
- DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases.